Skip to main
TELA

TELA Stock Forecast & Price Target

TELA Analyst Ratings

Based on 4 analyst ratings
Buy
Strong Buy 50%
Buy 25%
Hold 25%
Sell 0%
Strong Sell 0%

Bulls say

TELA Bio is well positioned to continue its upward revenue trend with a strong portfolio of OviTex products, demonstrated by impressive unit sales growth in the quarter and a solid gross margin of 65.9%. However, as reimbursement for certain healthcare procedures remains a key driver for TELA Bio's success, changes in reimbursement rates, especially in the evolving US healthcare landscape, could negatively impact the company's growth potential. Internationally, government control of pricing could also limit utilization of the company's products.

Bears say

TELA Bio is facing significant challenges that are impacting its financial performance and outlook, including an underwhelming first quarter and lowered full-year guidance for 2026. The company has had to navigate through sales force restructuring, strategic challenges, and lower than expected sales growth, which has led to a significant decrease in its stock price. While the company has a strong product portfolio, its concentrated focus on surgical mesh products and heavy reliance on regulatory approvals makes it vulnerable to potential disruptions and delays in the future. With these ongoing challenges, it is uncertain if TELA Bio will be able to successfully meet investor expectations and generate sustained growth.

TELA has been analyzed by 4 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 25% recommend Buy, 25% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of TELA Bio, Inc. and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About TELA Bio, Inc. (TELA) Forecast

Analysts have given TELA a Buy based on their latest research and market trends.

According to 4 analysts, TELA has a Buy consensus rating as of Aug 30, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $2, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $2, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

TELA Bio, Inc. (TELA)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.